ClinicalTrials.gg
CompletedNCT02409667OPTIMISEUpdated May 13, 2019Results posted

Plaque Psoriasis Efficacy and Safety With Secukinumab

A Phase 3 interventional study of Secukinumab in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 200 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16,487
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
Largest of 54
16,487 · median 124
Started
2015
with 6 others
Phase 3
24 of 54
none open now
Registered
25th of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one has the largest enrollment, is one of 7 that started in 2015, is one of 24 in phase 3, and was the 25th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c. every 4 weeks treatment with respect to maintaining a PASI 90 response rate at Week 52.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • plaque, psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Chronic plaque-type psoriasis diagnosed for at least 6 months prior to Screening and candidate for systemic therapy.
  2. Moderate to severe psoriasis at Baseline as evidenced by:

    • PASI ≥ 10 and
    • IGA mod 2011 score of 3 or higher (based on a scale of 0 to 4) and
    • BSA affected by plaque-type psoriasis of ≥ 10%.

Main Exclusion Criteria:

  1. History of exposure to any biologic drug taken for the treatment of chronic plaque psoriasis or any other indication including but not limited to anti-tumor necrosis factor (TNF) alpha, anti interleukin (IL)12/23, or any anti-IL 17A or IL 17A receptor (IL 17AR) antibody.
  2. History of to any of the study drugs or to drugs of similar chemical classes.
  3. Forms of psoriasis other than chronic plaque-type (eg, pustular, erythrodermic and guttate psoriasis).
  4. Drug-induced psoriasis (ie, new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium).
  5. Ongoing use of prohibited psoriasis treatments (eg, topical or systemic , ultraviolet (UV) therapy).
  6. Ongoing use of other non-psoriasis prohibited treatments. detailed in the protocol have to be adhered to. All other prior non-psoriasis concomitant treatments must be at a stable dose as detailed in the protocol before initiation of study drug.
  7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (> 5 mIU/mL).
  8. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of during dosing of study drug and for 16 weeks after stopping study drug.
  9. Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab therapy.
  10. Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions) which, in the opinion of the Investigator, significantly immunocompromises the patient and/or places the patient at unacceptable risk for receiving an immunomodulatory therapy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
16,487 participants (actual)

Study arms

  • Active comparator
    Secukinumab 300mg in PASI 90 responders (every 4 weeks)

    Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.

    Biological: Secukinumab

  • Experimental
    Secukinumab 300mg in PASI 90 responders (longer intervals)

    Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 6 weeks.

    Biological: Secukinumab

  • Experimental
    Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)

    Participants with moderate to severe plaque psoriasis who had reached PASI 75 to \<90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.

    Biological: Secukinumab

  • Active comparator
    Secukinumab 300mg in PASI 75-90 responders (shorter intervals)

    Participants with moderate to severe plaque psoriasis who had reached PASI 75 to \<90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 2 weeks.

    Biological: Secukinumab

Interventions

  • BiologicalSecukinumab

    Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.

06

What researchers measure

Primary outcomes

  1. Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24

    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: Week 52

Secondary outcomes

  1. Key Secondary: PASI 90 Response Rate at Week 52 in Participants With a PASI Response of ≥75 to <90 at Week 24

    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: Week 52

  2. PASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI 90 Response at Week 24

    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

    Time frame: week 52

  3. PASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI Response of ≥75 to <90 at Week 24

    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

    Time frame: Week 52

  4. Change From Baseline in PASI in Participants With a PASI 90 Response at Week 24

    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative change from baseline indicates improvement.

    Time frame: Baseline, Weeks 28, 32, 36, 40, 44, 48 and 52

  5. Change From Baseline in PASI in Participants With a PASI Response of ≥75 to <90 at Week 24

    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative change from baseline indicates improvement.

    Time frame: Baseline, Weeks 28, 32, 36, 40, 44, 48 and 52

  6. Change From Baseline in DLQI in Participants With a PASI 90 Response at Week 24

    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.

    Time frame: Baseline, Week 52

  7. Change From Baseline in DLQI in Participants With a PASI Response of ≥75 to <90 at Week 24

    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.

    Time frame: Baseline, Week 52

  8. Change From Baseline in Work Productivity and Activity Impairment Questionnaire - Psoriasis (WPAI-PSO) Score in Participants With a PASI 90 Response at Week 24

    The WPAI-PSO is a self-administered questionnaire comprised of 6 questions about effects of psoriasis on the patient's ability to work and perform regular activities based on the previous 7 days. The questionnaire quantifies the number of hours the respondent was unable to work and evaluates how much the respondent's psoriasis affected productivity while working. For respondents who were not in paid employment, the questionnaire evaluated how much the respondent's psoriasis affects their ability to perform regular daily activities. Four outcomes were generated from the WPAI-PSO: % Absenteeism: percent work time missed due to health; % Presenteism: percent impairment while working due to health; % Total work productivity impairment: percent overall work impairment due to health; % Total activity impairment: percent activity impairment due to health for all respondents. First 3 outcomes applied to employed participants only. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 52

  9. Change From Baseline in WPAI-PSO Score in Participants With a PASI Response of ≥75 to <90 at Week 24

    The WPAI-PSO is a self-administered questionnaire comprised of 6 questions about effects of psoriasis on the patient's ability to work and perform regular activities based on the previous 7 days. The questionnaire quantifies the number of hours the respondent was unable to work and evaluates how much the respondent's psoriasis affected productivity while working. For respondents who were not in paid employment, the questionnaire evaluated how much the respondent's psoriasis affects their ability to perform regular daily activities. Four outcomes were generated from the WPAI-PSO: % Absenteeism: percent work time missed due to health; % Presenteism: percent impairment while working due to health; % Total work productivity impairment: percent overall work impairment due to health; % Total activity impairment: percent activity impairment due to health for all respondents. First 3 outcomes applied to employed participants only. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 52

  10. Change From Baseline in Pain, Itching and Scaling Score in Participants With a PASI 90 Response at Week 24

    Self-administered, 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; and Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours? Patients had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) and the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category. A negative change from baseline indicates improvement

    Time frame: Baseline, Week 52

  11. Change From Baseline in Pain, Itching and Scaling Score in Participants With a PASI Response of ≥75 to <90 at Week 24

    Self-administered, 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; and Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours? Patients had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) and the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category. A negative change from baseline indicates improvement

    Time frame: Baseline, Week 52

  12. Change From Baseline in the European Quality of Life - 5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) in Participants With a PASI 90 Response at Week 24

    A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled "best imaginable health state" and "worst imaginable health state." This resulted in a numeric value set ranging from 0 (="worst imaginable health state") up to 100 (="best imaginable health state"). A positive change from baseline indicates improvement.

    Time frame: Baseline, Week 52

  13. Change From Baseline in the EQ-5D VAS in Participants With a PASI Response of ≥75 to <90 at Week 24

    A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled "best imaginable health state" and "worst imaginable health state." This resulted in a numeric value set ranging from 0 (="worst imaginable health state") up to 100 (="best imaginable health state").

    Time frame: Baseline, Week 52

  14. Change From Baseline in the EQ-5D Utility Index (Germany, United Kingdom (UK)) in Participants With a PASI 90 Response at Week 24

    The EQ-5D quantifies the health state of a patient for the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort \& anxiety/depression. In this study the EQ-5D-5L version has been used which evaluates each of these dimensions using the following 5 labels: no problems, slight problems, moderate problems, severe problems \& unable to/extreme problems. Based on the 5 dimensions, a summary score (utility index) was derived using country specific value sets evaluating the patient condition described by the outcome in the single dimensions. The EQ-5D-5L (in this trail) utility index based on the crosswalk value sets available from the EuroQol for Germany \& UK (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/) was calculated. A positive change from baseline indicates improvement. A visual analogue scale was used within the EQ-5D measuring the health state of the patients, ranging from 0 (worst imaginable health state) up to 100 (best imaginable health state).

    Time frame: Baseline, Week 52

  15. Change From Baseline in the EQ-5D Utility Index (Germany, UK) in Participants With a PASI Response of ≥75 to <90 at Week 24

    The EQ-5D quantifies the health state of a patient for the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. In the current study the EQ-5D-5L version has been used which evaluates each of these dimensions using the following five labels: "no problems", "slight problems", "moderate problems", "severe problems" and "unable to/extreme problems". Based on the five dimensions, a summary score (utility index) was derived using country specific value sets evaluating the patient condition described by the outcome in the single dimensions. For this trial, the EQ-5D-5L utility index based on the crosswalk value sets available from the EuroQol for Germany and for UK (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/) was calculated. A visual analogue scale (VAS) was used within the EQ-5D measuring the health state of the patients, ranging from 0 (="worst imaginable health state") up to 100 (="best imaginable health state").

    Time frame: Baseline, Week 52

07

Results

Posted May 13, 2019

Participant flow

Treatment Period 1, Baseline to Week 24
Participant flow — Treatment Period 1, Baseline to Week 24
MilestoneTreatment Period 1: All ParticipantsTreatment Period 2: Group 1Treatment Period 2: Group 2Treatment Period 2: Group 3Treatment Period 2: Group 4
Started16470000
Completed15260000
Not completed1210000
Withdrew: Withdrawal of informed consent60000
Withdrew: Withdrawal by subject60000
Withdrew: Protocol deviation200000
Withdrew: Pregnancy10000
Withdrew: Physician decision40000
Withdrew: Non-compliance with study treatment50000
Withdrew: Lost to follow-up60000
Withdrew: Lack of efficacy480000
Withdrew: Adverse event250000
Treatment Period 2, Week 24 to Week 52)
Participant flow — Treatment Period 2, Week 24 to Week 52)
MilestoneTreatment Period 1: All ParticipantsTreatment Period 2: Group 1Treatment Period 2: Group 2Treatment Period 2: Group 3Treatment Period 2: Group 4
Started064466211493
Completed062164110690
Not completed0232183
Withdrew: Lost to follow-up07430
Withdrew: Lack of efficacy00020
Withdrew: Adverse event07412
Withdrew: Withdrawal of informed consent05400
Withdrew: Withdrawal by subject04520
Withdrew: Pregnancy00101
Withdrew: Protocol deviation00300

Outcome measures

PrimaryMaintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
Week 52
Reported as:
Count of participants · Participants
Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24
ParticipantsTreatment Period 2: Group 1Treatment Period 2: Group 2
Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24552496
Statistical analysis
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · Regression, Logistic · p = 0.1499 · Odds ratio (or): 1.91 · 95% CI 1.44 to 2.55
SecondaryKey Secondary: PASI 90 Response Rate at Week 52 in Participants With a PASI Response of ≥75 to <90 at Week 24

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
Week 52
Reported as:
Count of participants · Participants
Key Secondary: PASI 90 Response Rate at Week 52 in Participants With a PASI Response of ≥75 to <90 at Week 24
ParticipantsTreatment Period 2: Group 3Treatment Period 2: Group 4
Key Secondary: PASI 90 Response Rate at Week 52 in Participants With a PASI Response of ≥75 to <90 at Week 245352
Statistical analysis
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · Regression, Logistic · p = 0.1013 · Odds ratio (or): 0.62 · 95% CI 0.35 to 1.10
SecondaryPASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI 90 Response at Week 24

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

Time frame:
week 52
Reported as:
Count of participants · Participants
PASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI 90 Response at Week 24
ParticipantsTreatment Period 2: Group 1Treatment Period 2: Group 2
PASI 50608624
PASI 75597588
PASI 90553496
PASI 100378305
IGA mod 2011564529
SecondaryPASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI Response of ≥75 to <90 at Week 24

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

Time frame:
Week 52
Reported as:
Count of participants · Participants
PASI 50, PASI 75, PASI 100 and IGA Mod 2011 0 or 1 Responders at Week 52 in Participants With a PASI Response of ≥75 to <90 at Week 24
ParticipantsTreatment Period 2: Group 3Treatment Period 2: Group 4
PASI 509888
PASI 757480
PASI 905352
PASI 1001213
IGA mod 2011 0 or 16472
SecondaryChange From Baseline in PASI in Participants With a PASI 90 Response at Week 24

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative change from baseline indicates improvement.

Time frame:
Baseline, Weeks 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · score on a scale
Change From Baseline in PASI in Participants With a PASI 90 Response at Week 24
score on a scaleTreatment Period 2: Group 1Treatment Period 2: Group 2
Week 28-20.7 ± 8.471-19.9 ± 8.511
Week 32-20.7 ± 8.581-19.8 ± 8.474
Week 36-20.6 ± 8.439-19.7 ± 8.563
Week 40-20.5 ± 8.392-19.6 ± 8.393
Week 44-20.5 ± 8.384-19.6 ± 8.484
Week 48-20.5 ± 8.472-19.2 ± 8.509
Week 52-20.4 ± 8.301-19.2 ± 8.513
Statistical analysis
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0489 · Least square mean (lsm) estimate: -0.09 · 95% CI -0.18 to -0.00
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.1073 · Lsm estimate: -0.09 · 95% CI -0.19 to 0.02
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0001 · Lsm estimate: -0.24 · 95% CI -0.37 to -0.12
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0005 · Lsm estimate: -0.25 · 95% CI -0.38 to -0.11
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0001 · Lsm estimate: -0.30 · 95% CI -0.45 to -0.15
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0000 · Lsm estimate: -0.49 · 95% CI -0.70 to -0.27
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0000 · Lsm mean: -0.59 · 95% CI -0.81 to -0.36
SecondaryChange From Baseline in PASI in Participants With a PASI Response of ≥75 to <90 at Week 24

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative change from baseline indicates improvement.

Time frame:
Baseline, Weeks 28, 32, 36, 40, 44, 48 and 52
Reported as:
Mean · score on a scale
Change From Baseline in PASI in Participants With a PASI Response of ≥75 to <90 at Week 24
score on a scaleTreatment Period 2: Group 3Treatment Period 2: Group 4
Week 28-16.1 ± 6.160-16.3 ± 8.029
Week 32-15.9 ± 6.002-16.6 ± 7.941
Week 36-16.1 ± 6.356-16.6 ± 7.996
Week 40-16.1 ± 6.908-16.8 ± 8.170
Week 44-16.1 ± 6.553-16.6 ± 8.259
Week 48-15.6 ± 6.246-16.8 ± 8.307
Week 52-15.5 ± 6.371-16.6 ± 8.011
Statistical analysis
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.1740 · Lsm estimate: 0.40 · 95% CI -0.18 to 0.99
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.0287 · Lsm estimate: 0.79 · 95% CI 0.08 to 1.50
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.1202 · Lsm estimate: 0.62 · 95% CI -0.16 to 1.41
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.1157 · Lsm estimate: 0.75 · 95% CI -0.19 to 1.68
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.3189 · Lsm estimate: 0.54 · 95% CI -0.52 to 1.59
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.0240 · Lsm estimate: 1.17 · 95% CI 0.16 to 2.18
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.0090 · Lsm estimate: 1.47 · 95% CI 0.37 to 2.57
SecondaryChange From Baseline in DLQI in Participants With a PASI 90 Response at Week 24

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in DLQI in Participants With a PASI 90 Response at Week 24
score on a scaleTreatment Period 2: Group 1Treatment Period 2: Group 2
Change From Baseline in DLQI in Participants With a PASI 90 Response at Week 24-12.7 ± 7.325-11.4 ± 7.480
Statistical analysis
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0001 · Lsm estimate: -0.62 · 95% CI -0.93 to -0.31
SecondaryChange From Baseline in DLQI in Participants With a PASI Response of ≥75 to <90 at Week 24

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in DLQI in Participants With a PASI Response of ≥75 to <90 at Week 24
score on a scaleTreatment Period 2: Group 3Treatment Period 2: Group 4
Change From Baseline in DLQI in Participants With a PASI Response of ≥75 to <90 at Week 24-10.0 ± 6.605-9.72 ± 6.880
Statistical analysis
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.0675 · Lsm estimate: 1.17 · 95% CI -0.09 to 2.42
SecondaryChange From Baseline in Work Productivity and Activity Impairment Questionnaire - Psoriasis (WPAI-PSO) Score in Participants With a PASI 90 Response at Week 24

The WPAI-PSO is a self-administered questionnaire comprised of 6 questions about effects of psoriasis on the patient's ability to work and perform regular activities based on the previous 7 days. The questionnaire quantifies the number of hours the respondent was unable to work and evaluates how much the respondent's psoriasis affected productivity while working. For respondents who were not in paid employment, the questionnaire evaluated how much the respondent's psoriasis affects their ability to perform regular daily activities. Four outcomes were generated from the WPAI-PSO: % Absenteeism: percent work time missed due to health; % Presenteism: percent impairment while working due to health; % Total work productivity impairment: percent overall work impairment due to health; % Total activity impairment: percent activity impairment due to health for all respondents. First 3 outcomes applied to employed participants only. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - Psoriasis (WPAI-PSO) Score in Participants With a PASI 90 Response at Week 24
score on a scaleTreatment Period 2: Group 1Treatment Period 2: Group 2
Absenteeism-4.70 ± 19.590-1.99 ± 19.759
Presenteeism-23.1 ± 25.968-23.0 ± 26.522
Total activity impairment-24.3 ± 27.850-23.2 ± 29.861
Work productivity loss-31.9 ± 29.392-28.6 ± 27.996
Statistical analysis
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.2101 · Lsm estimate: -0.97 · 95% CI -2.48 to 0.55
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.2971 · Lsm estimate: -0.67 · 95% CI -1.93 to 0.59
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.5499 · Lsm estimate: -0.61 · 95% CI -2.59 to 1.38
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0758 · Lsm estimate: -1.08 · 95% CI -2.28 to 0.11
SecondaryChange From Baseline in WPAI-PSO Score in Participants With a PASI Response of ≥75 to <90 at Week 24

The WPAI-PSO is a self-administered questionnaire comprised of 6 questions about effects of psoriasis on the patient's ability to work and perform regular activities based on the previous 7 days. The questionnaire quantifies the number of hours the respondent was unable to work and evaluates how much the respondent's psoriasis affected productivity while working. For respondents who were not in paid employment, the questionnaire evaluated how much the respondent's psoriasis affects their ability to perform regular daily activities. Four outcomes were generated from the WPAI-PSO: % Absenteeism: percent work time missed due to health; % Presenteism: percent impairment while working due to health; % Total work productivity impairment: percent overall work impairment due to health; % Total activity impairment: percent activity impairment due to health for all respondents. First 3 outcomes applied to employed participants only. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in WPAI-PSO Score in Participants With a PASI Response of ≥75 to <90 at Week 24
score on a scaleTreatment Period 2: Group 3Treatment Period 2: Group 4
Absenteeism-2.36 ± 12.990-3.45 ± 18.698
Presenteeism-22.9 ± 28.377-22.1 ± 26.333
Total activity impairment-23.1 ± 28.657-21.7 ± 29.905
Work productivity loss-18.2 ± 28.824-22.5 ± 25.192
Statistical analysis
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.4156 · Lsm estimate: 1.20 · 95% CI -1.71 to 4.11
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.8619 · Lsm estimate: 0.63 · 95% CI -6.59 to 7.85
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.6139 · Lsm estimate: -0.61 · 95% CI -6.31 to 10.61
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.5674 · Lsm estimate: 1.70 · 95% CI -4.16 to 7.56
SecondaryChange From Baseline in Pain, Itching and Scaling Score in Participants With a PASI 90 Response at Week 24

Self-administered, 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; and Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours? Patients had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) and the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category. A negative change from baseline indicates improvement

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in Pain, Itching and Scaling Score in Participants With a PASI 90 Response at Week 24
score on a scaleTreatment Period 2: Group 1Treatment Period 2: Group 2
Pain-4.56 ± 2.771-4.17 ± 2.2727
Itching-5.59 ± 2.885-5.20 ± 2.985
Scaling-6.05 ± 2.659-5.73 ± 2.757
Statistical analysis
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.1219 · Lsm estimate: -0.13 · 95% CI -0.30 to 0.04
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0001 · Lsm estimate: -0.38 · 95% CI -0.57 to -0.18
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0003 · Lsm estimate: -0.31 · 95% CI -0.48 to -0.14
SecondaryChange From Baseline in Pain, Itching and Scaling Score in Participants With a PASI Response of ≥75 to <90 at Week 24

Self-administered, 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching and scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; and Scaling: Overall, how severe was your psoriasis-related scaling over the past 24 hours? Patients had to rate their pain, itching, and scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) and the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category. A negative change from baseline indicates improvement

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in Pain, Itching and Scaling Score in Participants With a PASI Response of ≥75 to <90 at Week 24
score on a scaleTreatment Period 2: Group 3Treatment Period 2: Group 4
Pain-3.59 ± 2.754-3.68 ± 3.049
Itching-4.13 ± 2.883-4.49 ± 3.129
Scaling-4.66 ± 2.960-5.40 ± 2.899
Statistical analysis
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.6457 · Lsm estimate: 0.17 · 95% CI -0.57 to 0.92
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.6136 · Lsm estimate: 0.19 · 95% CI -0.56 to 0.94
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.0203 · Lsm estimate: 0.75 · 95% CI 0.12 to 1.39
SecondaryChange From Baseline in the European Quality of Life - 5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) in Participants With a PASI 90 Response at Week 24

A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled "best imaginable health state" and "worst imaginable health state." This resulted in a numeric value set ranging from 0 (="worst imaginable health state") up to 100 (="best imaginable health state"). A positive change from baseline indicates improvement.

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in the European Quality of Life - 5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) in Participants With a PASI 90 Response at Week 24
score on a scaleTreatment Period 2: Group 1Treatment Period 2: Group 2
Change From Baseline in the European Quality of Life - 5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) in Participants With a PASI 90 Response at Week 2424.34 ± 23.29621.24 ± 22.074
Statistical analysis
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0027 · Lsm estimate: 2.22 · 95% CI 0.77 to 3.68
SecondaryChange From Baseline in the EQ-5D VAS in Participants With a PASI Response of ≥75 to <90 at Week 24

A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled "best imaginable health state" and "worst imaginable health state." This resulted in a numeric value set ranging from 0 (="worst imaginable health state") up to 100 (="best imaginable health state").

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in the EQ-5D VAS in Participants With a PASI Response of ≥75 to <90 at Week 24
score on a scaleTreatment Period 2: Group 3Treatment Period 2: Group 4
Change From Baseline in the EQ-5D VAS in Participants With a PASI Response of ≥75 to <90 at Week 2415.86 ± 20.09918.92 ± 19.855
Statistical analysis
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.2823 · Lsm estimate: -2.31 · 95% CI -6.55 to 1.92
SecondaryChange From Baseline in the EQ-5D Utility Index (Germany, United Kingdom (UK)) in Participants With a PASI 90 Response at Week 24

The EQ-5D quantifies the health state of a patient for the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort \& anxiety/depression. In this study the EQ-5D-5L version has been used which evaluates each of these dimensions using the following 5 labels: no problems, slight problems, moderate problems, severe problems \& unable to/extreme problems. Based on the 5 dimensions, a summary score (utility index) was derived using country specific value sets evaluating the patient condition described by the outcome in the single dimensions. The EQ-5D-5L (in this trail) utility index based on the crosswalk value sets available from the EuroQol for Germany \& UK (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/) was calculated. A positive change from baseline indicates improvement. A visual analogue scale was used within the EQ-5D measuring the health state of the patients, ranging from 0 (worst imaginable health state) up to 100 (best imaginable health state).

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in the EQ-5D Utility Index (Germany, United Kingdom (UK)) in Participants With a PASI 90 Response at Week 24
score on a scaleTreatment Period 2: Group 1Treatment Period 2: Group 2
Germany0.17 ± 0.2000.13 ± 0.182
UK0.28 ± 0.2500.22 ± 0.230
Statistical analysis
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0861 · Lsm estimate: 0.01 · 95% CI -0.00 to 0.02
  • Treatment Period 2: Group 1 vs Treatment Period 2: Group 2 · ANCOVA · p = 0.0117 · Lsm estimate: 0.02 · 95% CI 0.00 to 0.04
SecondaryChange From Baseline in the EQ-5D Utility Index (Germany, UK) in Participants With a PASI Response of ≥75 to <90 at Week 24

The EQ-5D quantifies the health state of a patient for the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. In the current study the EQ-5D-5L version has been used which evaluates each of these dimensions using the following five labels: "no problems", "slight problems", "moderate problems", "severe problems" and "unable to/extreme problems". Based on the five dimensions, a summary score (utility index) was derived using country specific value sets evaluating the patient condition described by the outcome in the single dimensions. For this trial, the EQ-5D-5L utility index based on the crosswalk value sets available from the EuroQol for Germany and for UK (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/) was calculated. A visual analogue scale (VAS) was used within the EQ-5D measuring the health state of the patients, ranging from 0 (="worst imaginable health state") up to 100 (="best imaginable health state").

Time frame:
Baseline, Week 52
Reported as:
Mean · score on a scale
Change From Baseline in the EQ-5D Utility Index (Germany, UK) in Participants With a PASI Response of ≥75 to <90 at Week 24
score on a scaleTreatment Period 2: Group 3Treatment Period 2: Group 4
Germany0.11 ± 0.1640.13 ± 0.164
UK0.18 ± 0.2060.21 ± 0.204
Statistical analysis
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.1852 · Lsm estimate: -0.02 · 95% CI -0.05 to 0.01
  • Treatment Period 2: Group 3 vs Treatment Period 2: Group 4 · ANCOVA · p = 0.2203 · Lsm estimate: -0.03 · 95% CI -0.07 to 0.02

Adverse events

Collected over Week 52. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period 1: All Participants1/1,647 (0.1%)73/1,647 (4.4%)884/1,647 (53.7%)
Treatment Period 2: Group 10/644 (0%)25/644 (3.9%)272/644 (42.2%)
Treatment Period 2: Group 20/662 (0%)25/662 (3.8%)288/662 (43.5%)
Treatment Period 2: Group 30/114 (0%)4/114 (3.5%)64/114 (56.1%)
Treatment Period 2: Group 40/93 (0%)3/93 (3.2%)60/93 (64.5%)
Most frequent serious events
Showing 10 of 119
Most frequent serious events
EventTreatment Period 1: All ParticipantsTreatment Period 2: Group 1Treatment Period 2: Group 2Treatment Period 2: Group 3Treatment Period 2: Group 4
Respiratory tract infectionInfections and infestations0/16470/6440/6620/1141/93
Peripheral sensorimotor neuropathyNervous system disorders0/16470/6440/6620/1141/93
Deep vein thrombosisVascular disorders0/16470/6440/6620/1141/93
Angina pectorisCardiac disorders1/16470/6440/6621/1140/93
Myocardial infarctionCardiac disorders0/16470/6440/6621/1140/93
Alcoholic liver diseaseHepatobiliary disorders0/16470/6440/6621/1140/93
Urinary tract infectionInfections and infestations1/16470/6440/6621/1140/93
Alanine aminotransferase increasedInvestigations9/16471/6441/6621/1140/93
Aspartate aminotransferase increasedInvestigations10/16472/6441/6621/1140/93
OsteoarthritisMusculoskeletal and connective tissue disorders0/16470/6440/6621/1140/93
Most frequent other events
Showing 10 of 41
Most frequent other events
EventTreatment Period 1: All ParticipantsTreatment Period 2: Group 1Treatment Period 2: Group 2Treatment Period 2: Group 3Treatment Period 2: Group 4
Viral upper respiratory tract infectionInfections and infestations368/164794/64495/66223/11422/93
PsoriasisSkin and subcutaneous tissue disorders21/164712/64416/66211/1148/93
HeadacheNervous system disorders141/164731/64427/6626/1141/93
Upper respiratory tract infectionInfections and infestations65/164718/64416/6627/1145/93
DiarrhoeaGastrointestinal disorders74/164716/64422/6624/1140/93
InfluenzaInfections and infestations36/164717/64419/6624/1144/93
Alanine aminotransferase increasedInvestigations10/16474/6446/6622/1144/93
ArthralgiaMusculoskeletal and connective tissue disorders50/164716/64419/6623/1144/93
PruritusSkin and subcutaneous tissue disorders65/16479/64411/6622/1144/93
HypertensionVascular disorders55/16477/64410/6624/1144/93

Baseline characteristics

The safety set for Treatment Period 1 includes all subjects who took at least one dose of study treatment during this treatment period.

Age, Continuous
Age, Continuous(Years)Treatment Period 1: All Participants
Mean43.1 ± 13.38
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Period 1: All Participants
Female476
Male1171
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Period 1: All Participants
American Indian or Alaska Native0
Asian16
Native Hawaiian or Other Pacific Islander0
Black or African American4
White1597
More than one race0
Unknown or Not Reported30
08

Study locations

200 sites
  • Novartis Investigative Site
    Innsbruck, 6020, Austria
  • Novartis Investigative Site
    Linz, A-4020, Austria
  • Novartis Investigative Site
    Wien, 1090, Austria
  • Novartis Investigative Site
    Wien, A 1090, Austria
  • Novartis Investigative Site
    Jette, Brussel 1090, Belgium
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Loverval, 6280, Belgium
  • Novartis Investigative Site
    Sofia, BGR 1431, Bulgaria
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1404, Bulgaria
  • Novartis Investigative Site
    Sofia, 1407, Bulgaria
  • Novartis Investigative Site
    Stara Zagora, 6000, Bulgaria
  • Novartis Investigative Site
    Varna, 9000, Bulgaria
  • Novartis Investigative Site
    Ivanic Grad, 10310, Croatia
  • Novartis Investigative Site
    Osijek, 31000, Croatia
  • Novartis Investigative Site
    Zagreb, 10000, Croatia
  • Novartis Investigative Site
    Brno, Czech Republic 656 91, Czechia
  • Novartis Investigative Site
    Ostrava Poruba, Czech Republic 708 52, Czechia
  • Novartis Investigative Site
    Prague 8, Czech Republic 180 00, Czechia
  • Novartis Investigative Site
    Olomouc, 775 20, Czechia
  • Novartis Investigative Site
    Praha 10, 100 34, Czechia
  • Novartis Investigative Site
    Praha, 12808, Czechia
  • Novartis Investigative Site
    Arhus C, DK-8000, Denmark
  • Novartis Investigative Site
    Hellerup, DK-2900, Denmark
  • Novartis Investigative Site
    Tampere, 33100, Finland
  • Novartis Investigative Site
    Turku, FIN-20100, Finland
  • Novartis Investigative Site
    Le Mans, Cedex 09 72037, France
  • Novartis Investigative Site
    Bordeaux Cedex, 33075, France
  • Novartis Investigative Site
    Dijon, 21079, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Lille, 59000, France
  • Novartis Investigative Site
    Montpellier cedex 5, 34295, France
  • Novartis Investigative Site
    Nice, 06202, France
  • Novartis Investigative Site
    Rouen, 76031, France
  • Novartis Investigative Site
    Saint-Etienne, 42055, France
  • Novartis Investigative Site
    Toulouse Cedex, 31400, France
  • Novartis Investigative Site
    Trevenans, 90400, France
  • Novartis Investigative Site
    Vandoeuvre Les Nancy, 54511, France
  • Novartis Investigative Site
    Augsburg, 86179, Germany
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Berlin, 10783, Germany
  • Novartis Investigative Site
    Bochum, 44793, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Braunschweig, 38100, Germany
  • Novartis Investigative Site
    Dresden, 01069, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duesseldorf, 40212, Germany
  • Novartis Investigative Site
    Duesseldorf, D 40225, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Goettingen, 37075, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hamburg, 20354, Germany
  • Novartis Investigative Site
    Hamburg, 22391, Germany
  • Novartis Investigative Site
    Hanau, 63450, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Lubeck, 23538, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Muenchen, 81675, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Osnabrueck, 49074, Germany
  • Novartis Investigative Site
    Pommelsbrunn, 91224, Germany
  • Novartis Investigative Site
    Schwerin, 19055, Germany
  • Novartis Investigative Site
    Stade, 21682, Germany
  • Novartis Investigative Site
    Stuttgart, 70178, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Larissa, GR 411 10, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 546 29, Greece
  • Novartis Investigative Site
    Athens, 161 21, Greece
  • Novartis Investigative Site
    Thessaloniki, 546 43, Greece
  • Novartis Investigative Site
    Kecskemet, Bacs Kiskun 6000, Hungary
  • Novartis Investigative Site
    Budapest, 1085, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Kaposvar, 7400, Hungary
  • Novartis Investigative Site
    Pecs, 7632, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Afula, 1834111, Israel
  • Novartis Investigative Site
    Haifa, 3109601, Israel
  • Novartis Investigative Site
    Petach Tikva, 49100, Israel
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Tel Aviv, 64239, Israel
  • Novartis Investigative Site
    Bolzano, BZ 39100, Italy
  • Novartis Investigative Site
    Messina, ME 98125, Italy
  • Novartis Investigative Site
    Modena, MO 41124, Italy
  • Novartis Investigative Site
    Palermo, PA 90127, Italy
  • Novartis Investigative Site
    Roma, RM 00189, Italy
  • Novartis Investigative Site
    Daugavpils, LVA LV-5404, Latvia
  • Novartis Investigative Site
    Riga, LVA LV-1003, Latvia
  • Novartis Investigative Site
    Ventspils, LVA LV-3601, Latvia
  • Novartis Investigative Site
    Riga, 1012, Latvia
  • Novartis Investigative Site
    Riga, LV-1001, Latvia
  • Novartis Investigative Site
    Kaunas, LTU LT 50161, Lithuania
  • Novartis Investigative Site
    Klaipeda, LTU 92304, Lithuania
  • Novartis Investigative Site
    Kaunas, LT 47144, Lithuania
  • Novartis Investigative Site
    Vilnius, LT-07195, Lithuania
  • Novartis Investigative Site
    Vilnius, LT-08661, Lithuania
  • Novartis Investigative Site
    Breda, CK 4818, Netherlands

Showing the first 100 of 200 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Mar 2017, 22 months.

Results were first posted in May 2019, 2 years 1 month after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 22 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2015
First posted
Apr 7, 2015
StartActual
May 7, 2015
Primary completionActual
Mar 14, 2017
CompletionActual
May 8, 2017
Results first posted
May 13, 2019
Last update
May 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02409667
Responsible party
Sponsor
First posted
Apr 7, 2015
Start date
May 7, 2015
Primary completion
Mar 14, 2017
Completion
May 8, 2017
Results posted
May 13, 2019
Last update
May 13, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion